Embed Size (px)
Citation preview
Investor Deck September 2017
TÉCNICAS BIOMÉDICAS PARA LA SALUD (TBIOM)
TBIOM (Técnicas Biomédicas para laSalud, S.L.) is a top innovative SME, spin-off from FCTecnics established in September 2015. It is located in Sant Adrià de Besòs, Barcelona, with 280m2 of space workshop, storeroom, laboratory and technical office. TBIOM is currently developing on and releasing a new medical device (CPAP) for the treatment of Obstructive Sleep Apnea (OSA).
Current company’s capital is 488.000€, entirely dedicated to the development and introduction into the market of the new device. Such capital has been invested by the founding partners and a group of crowdfunding investors reached through CapitalCell platform. TBIOM is the proprietor of the patent P3280PC00 already obtained in the domestic market and is also solliciting the PCT to expand the shelter overseas.
The present document summarizes several aspects so essential from the business plan and finantial forecomings of TBIOM. The aim in itself is offering to the investor a loyal and trusting image and future perspectives. As TBIOM is such a developing and expanding firm also the document is valid to 30th September 2017. The data and forecomings currently enclosed has not to do with contractual issues._____________________TBIOM SLc/ Atlàntida 21, 2º 2ª08930 Sant Adrià Besòs (Barcelona)[email protected]
Tested in Android and IOS with QR Droid and ScanLife
What is Sleep Apnea? The Obstructive Sleep Apnea (OSA) is a common disorder where breathing is interrupted or becomes very superficial during sleep. These interruptions can last from very few seconds to minutes and can occur more than 30 times per hour. During apnea the breathing stops while the person is sleeping. This happens due to the airway became narrower or partially blocked.
When the muscles on the upper part of the throat get relaxed during sleep, the tissues close up and block the airway. This stop during breathing is called apnea.
Loud snoring is a warning symptom for OSA. Snoring is caused by the air that slips through a narrow or blocked airway. Even though, not all people that snore suffer from sleep apnea. Sleep apnea is the triggering effect for multiple pathologies such as depression, arrhythmias or hypertension.
In Spain there are between 1 and 2 million people who suffer from OSA (4% of the population). 65% of these people are also overweight.
4% of Spanish people suffer from sleep apnea. The majority of them are overweight.
It has also a high incidence on people who suffer Down Syndrome, Multiple Sclerosis and athletes who have developed a great musculature as a consequence of their activities. The most commonly accepted treatment by the medical community is the use of a CPAP device (Continuous Positive Airway Pressure). ¿What means Sleep Apnea and how
to recognise it?http://bit.ly/promo_airmony_EN_15s
Tested in Android and IOS with QR Droid and ScanLife
Current CPAPsThe most common CPAPs in the market (a 98%), are desktop devices that are connected to the electricity grid and that transfer pressurized air from a device that is located far away from the patient to the user’s mask through a corrugated tube. They are typically devices of a noteworthy size, weight and volume. In conclusion, devices that are designed to stay in place on a nightstand.
The current tendency of the market is to cut down the volume of CPAP devices as the current size and weight of the gadget and the fact that it needs a tube between the equipment and the mask of the patient supposes an important inconvenience when bringing the CPAP around.
CPAP users almost always have to travel with an extra suitcase for their device. Also, current CPAPs have to be plugged into the electrical grid and thus, reduces the possibility of users to commute to places where the access to electricity is limited, such as transportation (planes, trains) or camping sites.
Dimensions and the fact that there is a tube make it difficult for patients to move around with their device.
Nowadays, there is no CPAP in the market which works with e-health technology therefore monitoring physiologic parameters from the patient, and doesn’t need a tube.
Advantages
Presentation Video
Promotional video. Airmony, the air you dream ofhttp://bit.ly/videoairmonyEN
General video of the companyhttp://bit.ly/gral_tbiom
● TUBELESS● PORTABLE● USB● SCALABILITY● SILENT● MONITOR● CONNECTIVITY● WASHABLE● LOW
CONSUMPTION
Patent We currently own the Spanish patent P3280ES00 of the 7th April 2015 (portable and autonomous air
impeller device that provides assisted ventilation in the treatment of Sleep Apnea Syndrome for people
affected from SAHS and to improve night sleep on elite and/or high performance athletes.) Likewise we
have requested the International PCT that will allow us to protect our technology in the markets where
we want to commercialise our product (Europe and USA).
In our PCT Patent , there are multiple novelties compared to the traditional devices. To emphasise: the
elimination of the corrugated tube, which makes it easier to have proximity sensors on the user’s skin
(suitable to reduce size and also to transform the CPAP into a health manager) and a particular orientation
of the bomb blades, that makes flows and negative dynamic answers possible without inverting the spin
direction.
Nevertheless, the elimination of the exhalation valve that all current CPAPs have in the elbow joint
between the tube and the mask to avoid rebreathing (an effect that is produced if the patient would
breathe again the air that they have previously exhaled) is, without a doubt, the most important advance
that, from a technological point of view, our invention provides and it’s registered in our patent.
The elimination of the exhalation valve is possible thanks to the special design of the blades and the fact that
the exhaled air has to go through a very short distance to expell. This feature allows that the impelled air is
really used by the patient (and not like nowadays, where there is a 75% more air impelled than necessary),
this allows a drastic reduction of the bombing power, perfect to take a step further to the pocket CPAP
since it needs a much smaller motor-
The company is in constant technical evolution following a strategy to protect its intellectual and industrial
property. We are currently working on to obtain new patents for our developments.
m-health Connectivity
Simple but effective. Airmony’s Bluetooth system allows precise sleep monitoring.
Complementary services
Simple but effective
MultiplatformA web which gives to the specialist the tools to design
interactions, receive parameters and analyze health
data from patients. This allows constant monitoring
and easy medical intervention if needed. There is also
the possibility to maintain a real time medical consult.
An intuitive App for the patient which enables a continuous communication path with the doctor, to describe symptoms, ask about diagnostics
Connect several e-health devices. Specially Airmony, our CPAP.
Information and data secured among the different system actors.
Software
INTEGRATED DATA
Medical monitoring platform
based on a Cloud infrastructure.
The patient can check the
medical data provided by
Airmony as well as from many
other m-health devices
(tensiometer, scales…).
Specialists have access to a
screen with a global vision of
captured data. A colour code
gives the doctor the information
regarding the need of analysing,
revising or changing the
treatment.
NOTIFICATIONS
The doctor can fix parameters to manage group or individual notifications according to data. The doctor or caretaker receives notifications through colour codes.
DATA GRAPHICS
The doctor can access in a visual way to registered data. The doctor can create a series of queries simulating medical consultation. The doctor can directly communicate with the patient through text messages and propose video consulting.
CLINICAL WORKFLOW
The doctor can create a series of queries simulating medical concealling.
The patient can access all queries through the App.
Team
Jaume Palou CEO
Francesc MartínezCommercial Director
Miquel Sisteré Medical Director
Xavier Soucheiron Advisor
Jordi PetitFinancial Director
Tested in Android and IOS with QR Droid and ScanLife
Project development
V.1 AppSoftware
Constitution
Investment Forum
V.0 Test in Thailand
Seal of ExcellenceV.1 Test
Dr. Estivill
FemindustriaAward
Crowdfunding closing
PrototypeV.2
November
December
Crowdfunding start
Spanish patent
Congress poster
Santander
EmpentaProgram
Int. Congress
Praga
Medical FairDusseldorf
Clinical Trial
V.3Definitive
Industriali-zation
SALESSTART
Round B400 k
Pilot test Dr.
Estivill
Round C1100 k
MarketIn Europe and USA there is 100M of people affected by Sleep Apnea (OSA),
around a 15% of the total population. Only a 20% of this people are
diagnosed by specialists and are traditional CPAP users. Between a 5-8%
(1,6M) of this population that are already users have the need for commuting,
for business or leisure, and can’t use a CPAP in transportation such as planes
or where no electrical power system is available, also there is the
inconvenience of travelling with a suitcase dedicated to the CPAP. In Spain, at
the end of 2016 there was more than 400.000 devices in use, which supposes
between a 5-7% of the diagnosed and treated average cases, according to a
study from the Pulmonology and Thoracic Surgery Association.
Worldwide, this means a mature market that is not saturated. Every CPAP
user and Sleep Apnea sufferer that has been already diagnosed knows their
need and values the advantages that Airmony offers from an experience and
therapeutic point of view. It isn’t a saturated market since the annual growth
index is around a 10%. This growth is justified by the current infra diagnosis
that is being eventually overcome due to the raising awareness of the
importance of a good rest for an optimal and healthy life, as well as the need of
replacing the devices due to its obsolescence.
100 M. Affected
20 M. Diagnosed
Fuertes Incrementos Anuales
Affected
User
The main target is a male of 45 to 70 who suffers from OSA and is diagnosed and due to professional or leisure reasons has to come and fro.
AgeOccupation
StatusNationality
StylePatient
VALUES
Profession
Health
Travel
Family
Leisure
BIO45-70 Professor/Business MarriedUSA/EuropeUrbanSleep Apnea
Competence
In the top league from CPAPs are involved big multinationals tracing such as PHILIPS RESPIRONICS, firm related to Phillips Healthcare. Another manufacturing firms of CPAPs to the top range are BREAS and RESMED.
At hand the market follows two trends. In a side the top exigence of devices every time more tiny, lighter and portable. On the other side, the connectivity linked to the integration of the devices in mobile applications multi plattform ehealth.
BRAND MODEL Db HOSELESS WEIGHT ECG BLUETOOTH APP
MULTIPLAT EHEALTH BATTERY PRICE
TBIOM Airmony 25 YES 125g YES YES YES YES > 2 nights 1499€
BREAS Z1 25 NO 500g NO YES NO NO 1 night 1218€
RESMED Airmini 25 NO 300g NO YES NO NO NO 1750€
PHILIPS Dreamstation Go 25 NO 900g NO YES NO YES 1 night 1000€
TRANSCEND MiniCpap 26.6 NO 436g NO NO NO NO 1 night 695€
Business Model
Airmony
The main business model of the company is based on the
commercialization and direct sales of Airmony devices, through physical and web distributors. Nowadays, online distribution,
especially in markets like USA is gaining market rate. Distribution through local physical distributors
will be initiated in Europe (Spain/France/Germany). 4
distributors have already shown interest.
Software as a Service
E-health multiplatform software application linked to Airmony offers telemedicine services to
monitor the different pathologies of the patients. The user can access his data, link several mhealth devices and perform real time video with specialists. The Danish versions of this platform has already 150.000
users.
Cloud
Exploitation of the data base generated. The connection of Airmony to the Cloud allows anonymous and automatic register of data related to
sleep segmented form from the patients of OSA about
sleep habits and use conditions.
Accessories
Sales and distribution of accessories is expected to overcome the 15% of the
annual business volume of the company. Transport
cases, cleaning kits, replacement filters,
replacement batteries, cables, so on.
Canvas model
Canvas model
Marketing and communicationThe marketing and communication strategy of AIRMONY is based on market penetration through various complementary and coadjuvant routes.
In most of the cases, the doctor will be the one to inform the patient about CPAPs in the market and to give advice to them. Airmony has been presented in the National Congress of Sleep Medicine in Santander with Dr. Estivill. Presentation from a study performed by Dr. Estivill about soak up of dates in Prague International Congress (October 17th).Presentations will be performed and we will be enrolled in different international events to be promoted in the medical community. From the advantages and characteristics of Airmony these traditional marketing actions will be key considered in the setting of the product and will be developed in such several geographical areas in partnership with the local distributors. As well as is foreseen the presence in means of communication and specialised magazines.
The distributor of devices CPAP has special importance in such specific markets as can be the European one. It’s defined a leak strategy in the markets due to the volume and permeability. The introduction in the market is done through a selection of agreements with local partners in every country or countryshire. In very markets, as USA, online distribution is taking every more time a big importance as mean of selling. More and more often there are more web distributors of CPAP devices.
Every more efforts are made with the vivid presence in fairs and international events where medical devices are present.
The come across with the final user is considered essential to the selling process and the final decision. The user or future user of CPAP has the availability to assess the enhances and chances that different devices from the market can offer. A constant changing of tendency from the competing firms towards a communication every time more effective to the user. Top importance in social nets and media in the introduction of new devices focused on big markets. There are already 30 pre-selling and 90 waiting requests of selling. (3 months hot promotion).
Doctor Distribution User
Sales Forecast
As a first step, needed inversions are exposed to the development of I+D Airmony as well as the commercial launching that together with our cash needs, offers us a vision of the financial requirements of the company.
To end up, payments and expenses forecomings (P&G) for the next five years, forecast period to the launching of the inversion.
INVESTMENTS
FINANCIAL NEEDS
BALANCE. FORECAST PAYMENTS & EXPENSES ACCOUNT FORECAST
SALES FORECAST
COST PER UNIT ANALYSIS
Investments
Cost per unit analysis
Sales Forecast
Active Balance
Passive Balance
Payments & Expenses Account
Financial Needs
EvolutionMAGNITUDES EVOLUTION
EBITDA
DISTRIBUTION MARGIN
GROSS MARGIN
Pre-money valuation The pre-money estimation nowadays is established in 4 Million Euros (September 2017). This is based in the following criteria:
Previous valuesIn March 2017 we launched the first round with pre-money worth 1.8M. As a result.
Time to marketCurrently, we still are in 11 months to launch the product in the European markets. (September 2018)
Technical RisksWe are on disposal of the pre-functional prototype checked in clinical tests and lab tests. Certification process has benn started.
PatentWe have already obtained the Spanish patent with no opposal and currently are taking into account the penetration in the market of PCT to other markets.
Commercial risksIs currently developed in the European commercial net through contacts with the main European distributors, working on fairs of the sector (Medica 2017) and presentations in medical congress (Santander and Praga).
BalanceBetween different elements and technical and commercial risks, the scaling of the product, equipment capacity, access time and size of the market makes necessary a tailored funding will be fitted to the objectives and money invested.
Why invest in Airmony?
Sheltered by International Patent Intellectual property strategy of protection.
A recognised interest from the scientific and medical community
Active presence in International Congresses.
Constantly growing market Appealing market with substantial margins of benefit.
Rapid penetration in the market Counting with existing distributors and online strategy
Innovative Medical Device Technically advanced in a sector with great multipliers.
Ehealth platform Completely integrated.
Revolution in the sectorKeeps aside competence products.
Easy and scalable productionLow turnover and management costs
Additional Information
What is a sleep apnea and how to recognize it?http://bit.ly/promo_airmony_EN_15s
Estivill speaks at RTVE about Albert Llovera's sleep on the Dakar with CPAP Airmony by Tbiom RTVEhttp://bit.ly/promo_airmony
Albert Llovera explains his experience with CPAP Airmony in the Dakarhttp://bit.ly/llovera_dakar2017
CPAP Airmony for sleep apnea, in Els Diners TV3http://bit.ly/AirmonyTV3
CPAP Airmony by TBiom in Vallès Visióhttp://bit.ly/promo_airmony_EN_15s
Tested in Android and IOS with QR Droid and ScanLife
Additional Information
Locationhttp://bit.ly/locTBIOM
TBIOM websitehttp://bit.ly/TBIOM
Airmony websitehttp://bit.ly/AirmonyEN
Airmony bloghttp://bit.ly/blogairmonyEN
Recent crowdfunding campaign Indiegogohttp://bit.ly/Airmony
Facebookhttp://bit.ly/TBIOMED
Twitterhttp://bit.ly/TbioMedEN
Tested in Android and IOS with QR Droid and ScanLife
Facilities
